Another Covid-19 vaccine in China is listed with conditions.

Xinhua News Agency, Beijing, February 6 (Reporter Dong Ruifeng) The inactivated Covid-19 vaccine "Kelaifu" of Beijing Kexing Zhongwei Biotechnology Co., Ltd. was approved for conditional marketing on the 5th, which is the second Covid-19 vaccine approved in China.

National Medical Products Administration official website news shows that National Medical Products Administration is based on the Vaccine Management Law and the Drug Administration Law.Relevant regulations, in accordance with the special drug approval procedures, emergency review and approval, conditional approval of the vaccine marketing registration application.

Kexing Zhongwei later said that the vaccine was made by inoculating African green monkey kidney cells (Vero cells for short) with Covid-19 (CZ02 strain), culturing, harvesting virus liquid, inactivating virus, concentrating, purifying and adsorbing with aluminum hydroxide, and it contained no preservatives. The basic immunization program of the vaccine is 2 doses, with an interval of 14 days to 28 days, and the dosage for each human use is 0.5 ml.

In June 2020, the vaccine was approved for emergency use in China. Since January 2021, Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay and other countries have successively approved the local emergency use of the vaccine.

According to the regulations of National Medical Products Administration, the holder of vaccine marketing license should continue to carry out relevant research work, complete the conditional requirements and submit the follow-up research results in time.

Previously, the Covid-19 inactivated vaccine of Sinopharm Group China Bio has been approved by National Medical Products Administration for conditional marketing. China plans to establish an immune barrier for the whole population through vaccination, and provide Covid-19 vaccine to the whole people free of charge.